NCT02457910: Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

NCT02457910
Breast Cancer Type: HR+ & HER2-Negative, Triple Negative
Hormone Mutations: ER+, PR+, AR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: HR+ & HER2-negative are only eligible for phase 1; TNBC patients are only eligible for phase 2; Must be AR+
Exclusions: Current or previously treated brain metastasis or active leptomeningeal disease 
https://ClinicalTrials.gov/show/NCT02457910

Comments are closed.

Up ↑